Determining the right prostate cancer treatment for you
Following a cancer diagnosis, it’s natural to feel overwhelmed, making it challenging to decide on the right treatment option. Many people report feeling lost about next steps and a need for deeper education about their options.
The ArteraAI Prostate Test is an artificial intelligence precision medicine test, designed to help clinicians and patients come to a shared decision on the optimal personalized treatment plan.
Where does the ArteraAI Prostate test fit in the patient journey?
The test is designed to support clinical decision-making through risk stratification, determining suitability for active surveillance, and prediction of ST-ADT benefit for patients with localized prostate cancer.
How the ArteraAI Prostate Test helps
Recommended in NCCN Guidelines
Multimodal AI (ArteraAI Prostate Test) has undergone rigorous validation and is supported by trusted entities in cancer care, including the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer.Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed June 4, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. NCCN, National Comprehensive Cancer Network.
Fast turnaround with no additional procedures
The ArteraAI Prostate Test does not require any additional procedures because it uses the digitized image of a patient’s existing biopsy sample. Results can be shared within 2-3 days after receipt of the patient’s biopsy slide.
Financial options available
Medicare (CMS) has established a payment rate for the ArteraAI Prostate Test. Artera also offers a financial assistance program for patients covered by commercial insurance and may have large out-of-pocket costs.
Minimizing the side effects of unnecessary treatment during cancer care
The standard of care for intermediate-risk localized prostate cancer is short-term androgen-deprivation therapy (ST-ADT) in combination with radiation therapy (RT + ST-ADT), but only ⅓ of patients may benefit from intensified treatment with ADT. ADT can have devastating side effects, such as sexual dysfunction, cognitive impairment, and metabolic syndrome.Spratt DE, et al. NEJM Evidence. 2023;2(8):EVIDoa2300023. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300023
Patients who find they will benefit from ADT can be confident in their decision to proceed with treatment, knowing that they are on an ideal course for their care. Conversely, patients whose results indicate no clear benefit from ADT can also feel confident in their choice to forego the treatment, assured that they are making the best decision for their health.
How one patient found peace of mind with ArteraAI
“I was looking for a treatment that could give me a better quality of life by minimizing the side effects….the ArteraAI Prostate Test revealed that I could avoid ADT and my treatment went well. I’m very glad I was able to avoid ADT.”
With ArteraAI Prostate Test
The AI identifies the 34% of patients who may greatly benefit from short-term hormone therapy.
AI Biomarker Negative
Identify patients who may not need short-term
hormone therapy.
Hazard ratio: 0.92 (95% CI, 0.59-1.43, P = 0.71)
n = 1046 patients studied
AI Biomarker Positive
Identify patients who may greatly benefit from short-term
hormone therapy.
Hazard ratio: 0.34 (95% CI, 0.19-0.63, P < 0.001)
n = 673 patients studied
ArteraAI Prostate Test Guide 2024
This test is for patients who have been diagnosed with localized prostate cancer who have not yet received radiation therapy.
Mind the Gap
While all men are at risk for prostate cancer, there are disproportionate gaps in treatment, research, clinical trials and mortality rates among African American men that need to be recognized and can be addressed with the aid of AI
Plain Language Summary
This summary is for anyone who wants to learn more about tools that help determine treatment in men with prostate cancer.
ArteraAI Prostate Test Brochure
This brochure provides more information about how the ArteraAI Prostate Test works.
Frequently asked questions
Explore our FAQ section to find straightforward answers to your questions about the ArteraAI Prostate Test.
-
The ArteraAI Prostate Test is intended to help clinicians determine the therapeutic benefit for patients who have been diagnosed with localized prostate cancer who have not yet received radiation therapy (RT) or androgen deprivation therapy (ADT) before getting a biopsy.
-
The out-of-pocket cost for the ArteraAI Prostate Test will be based on your insurance plan. If you are covered by Medicare Plan B, you should have zero out-of-pocket costs for the ArteraAI Prostate Test. If you are covered by private insurance, financial liability will be subject to the terms of your plan taking into consideration copays, coinsurance and deductibles. You should contact billing@artera.ai for additional details about the estimated out-of-pocket liability for the test.
-
Results can be shared within 2-3 days after receipt of the patient’s specimen.
-
The ArteraAI Prostate Test offers prognostic and predictive insights. The prognostic information includes a score indicating various risks for you, like metastasis (cancer spreading) and survival, while predictive information informs whether you are likely to benefit from a specific therapy, e.g., a hormone therapy or androgen deprivation therapy (ADT).
-
The ArteraAI Prostate Test does not require any additional procedures, as it relies on your existing biopsy sample. The test also does not consume any tissue so it will not impact the ability to run additional tests that may need to consume tissue.
-
The ArteraAI Prostate Test has undergone rigorous validation. The algorithm has been developed using large sets of data, from thousands of patients and tens of thousands of pathology slide images (digitally scanned tissue slides) and has been clinically validated using many Phase 3 randomized trials. Multiple Phase 3 randomized trials with up to 15-year follow-ups were used to develop and validate the prognostic and predictive AI models.
-
The ArteraAI Prostate Test can increase your confidence by offering more clarity around your optimal treatment path, allowing you to engage in shared decision-making with your clinician.
-
The ArteraAI Prostate Test uses existing biopsy slides and does not consume tissue or require additional biopsies. As there are no additional medical procedures required for this test, there are no side effects or complications to be concerned about.
-
The ArteraAI Prostate Test is available as part of Artera’s CLIA-certified laboratory developed test (LDT) service. These tests have not been cleared nor approved by the FDA.
Be your own advocate! Share this information with your doctor today. Send to doctor
